Apnimed, Inc. (APMD)

Price$27.45Cached quoteAs of 2026-09-05 03:33 UTC

AI: Fair-priced

Price checkThe valuation looks balanced because strong cash support meets a costly approval gamble.

Using 41.63 million shares outstanding after the offering, the observed price implies about $1.13 billion of equity value. Add June cash of $172.8 million and $200.4 million of net offering proceeds, then subtract roughly $50 million of debt and revenue-linked obligations, and the business itself is valued near $810 million, before later spending. As an illustrative yardstick, valuing a mature drug company at four dollars per dollar of annual sales would require about $200 million of sales before approval risk or option dilution.

Big pictureReported profits hide a business still consuming cash without an approved product.

Apnimed has no approved product; reported revenue came from partnership-related arrangements, not recurring medicine sales. In 2025, revenue rose to $38.5 million, yet the operating loss was $53.8 million and operations used $77.8 million of cash, versus $110.2 million in 2024. The second-quarter 2026 profit of $125.9 million was driven by one-time gains of $85.4 million and $57.1 million, while operations lost $11.7 million. Sleep-apnea demand is not very cyclical, but this stock remains highly event-driven.

Business strengthLate-stage proof and ample funding improve the odds, while dilution reduces each share’s claim.

Both approval-stage trials met their main goal, and the application is supported by roughly 1,300 patients. SynAIRgy showed a 44.7% reduction in low-oxygen burden among treated patients versus 8.5% with placebo, while key patents are expected to last until at least 2038. June cash plus net offering proceeds totaled about $373 million, supporting management’s plan through June 2028. However, 13.8 million new shares became roughly one-third of post-offering shares, and about 9.6 million outstanding options create further potential dilution.

What could change the storyA broad approval could unlock a huge market; weak patient uptake would break the case.

The regulator’s February 28, 2027 decision is the clearest swing factor. Broad approval, insurer coverage, and evidence that patients remain on treatment could open an estimated 80 million-person United States market to the first oral therapy aimed at airway-muscle control. The bear case is concrete: this is Apnimed’s only clinical product, and 21.2% of SynAIRgy patients stopped treatment because of side effects versus 3.1% on placebo. Rejection, restrictive safety wording, or weak early prescriptions would undermine the roughly $810 million product value embedded today.

AI: News

Application accepted for reviewRegulators accepted the sleep-apnea pill for review, creating a dated approval decision.

On July 14, the regulator accepted AD109 for review and set February 28, 2027 as its decision target. Acceptance means the application was complete enough to review, not that approval is likely or guaranteed. The filing draws on two randomized Phase 3 trials covering mild through severe obstructive sleep apnea; both met their main breathing-event goal. Because Apnimed was still private, there was no public-share reaction to measure. The event reduces filing risk and concentrates value on the coming decision.

Upsized public offeringThe upsized public offering funded launch preparation but expanded the share count substantially.

Apnimed closed its offering on August 3, selling 13.8 million shares, including the full extra allotment, for $220.8 million gross and about $200.4 million net. Those shares were roughly one-third of the 41.62 million post-offering total, so the cash cushion came with dilution. On its July 31 debut, the stock closed 56% above the offer price after a volatility halt. That reaction shows strong initial demand, but not proof of eventual drug approval or sales.

Quarterly cash updateFresh cash improved survival odds, while launch spending rose before any approval.

On September 8, Apnimed reported $172.8 million of June cash. Research spending fell 38% to $9.9 million as trials ended, while administrative spending more than doubled to $12.7 million as launch preparation began. The $125.9 million quarterly profit chiefly reflected two one-time gains totaling $142.5 million, not repeatable medicine earnings. Shares fell about 2.5% in the next session, but timing alone cannot establish that the update caused the move.

Loading local price history

Revenue

2024

2025

Net income

2024

2025

Free cash flow

2024

Total cash / debt

CashTotal debt

2024

2025

Financial statements

	2025	2024
Revenue	$38.5M	$8.0M
Research & development	$141.7M	$6.3M
Operating expenses	$85.6M	$118.9M
Operating income	−$53.8M	−$114.2M
Operating margin	−139.91%	−1,425.79%
EBITDA	−$53.8M	−$114.2M
EBITDA margin	−139.84%	−1,425.50%
Net income	−$70.1M	−$2.7M
Net profit margin	−182.34%	−33.75%
Basic EPSper basic share	-$0.03	-$3.87
Diluted EPSper diluted share	-$0.03	-$3.87